Cover Image

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterlo...

Full description

Saved in:
Bibliographic Details
Main Authors: Benza, Raymond L. (Author) , Langleben, David (Author) , Hemnes, Anna R. (Author) , Noordegraaf, Anton Vonk (Author) , Rosenkranz, Stephan (Author) , Thenappan, Thenappan (Author) , Hassoun, Paul M. (Author) , Preston, Ioana R. (Author) , Ghio, Stefano (Author) , Badagliacca, Roberto (Author) , Vizza, Carmine D. (Author) , Lang, Irene M. (Author) , Meier, Christian (Author) , Grünig, Ekkehard (Author)
Format: Article (Journal)
Language:English
Published: [2022]
In: European respiratory review
Year: 2022, Volume: 31, Issue: 166, Pages: 1-12
ISSN:1600-0617
DOI:10.1183/16000617.0061-2022
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1183/16000617.0061-2022
Verlag, lizenzpflichtig, Volltext: https://err.ersjournals.com/content/31/166/220061
Get full text
Author Notes:Raymond L. Benza, David Langleben, Anna R. Hemnes, Anton Vonk Noordegraaf, Stephan Rosenkranz, Thenappan Thenappan, Paul M. Hassoun, Ioana R. Preston, Stefano Ghio, Roberto Badagliacca, Carmine D. Vizza, Irene M. Lang, Christian Meier and Ekkehard Grünig
Description
Summary:Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH. - Tweetable abstract ERSpublications - click to tweetRaymond L. Benza (@OSUWexMed) and co-authors review the current evidence showing the effect of riociguat on right ventricle remodelling, function and structural parameters in preclinical models and patients with #PAH or #CTEPH. #pulmonaryhypertension https://bit.ly/3Q9icVm
Item Description:Gesehen am 01.02.2023
Physical Description:Online Resource
ISSN:1600-0617
DOI:10.1183/16000617.0061-2022

Similar Items